Geode Capital Management LLC Grows Stake in Celldex Therapeutics, Inc. $CLDX

Geode Capital Management LLC raised its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 5.2% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,672,980 shares of the biopharmaceutical company’s stock after purchasing an additional 83,174 shares during the quarter. Geode Capital Management LLC’s holdings in Celldex Therapeutics were worth $34,050,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC boosted its stake in Celldex Therapeutics by 171.7% during the second quarter. Nisa Investment Advisors LLC now owns 1,394 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 881 shares in the last quarter. AlphaQuest LLC boosted its holdings in Celldex Therapeutics by 182.5% in the first quarter. AlphaQuest LLC now owns 12,112 shares of the biopharmaceutical company’s stock worth $220,000 after purchasing an additional 7,825 shares during the last quarter. ADAR1 Capital Management LLC purchased a new stake in Celldex Therapeutics during the first quarter valued at $265,000. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Celldex Therapeutics in the 1st quarter worth approximately $269,000. Finally, Jump Financial LLC grew its position in shares of Celldex Therapeutics by 16.6% during the 1st quarter. Jump Financial LLC now owns 19,248 shares of the biopharmaceutical company’s stock valued at $349,000 after acquiring an additional 2,735 shares during the period.

Celldex Therapeutics Stock Up 1.3%

Shares of Celldex Therapeutics stock opened at $26.79 on Thursday. Celldex Therapeutics, Inc. has a 52-week low of $14.40 and a 52-week high of $29.05. The firm’s 50 day moving average price is $25.78 and its 200-day moving average price is $23.21. The company has a market cap of $1.78 billion, a P/E ratio of -8.90 and a beta of 1.36.

Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Monday, November 10th. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.13). Celldex Therapeutics had a negative return on equity of 27.61% and a negative net margin of 3,446.88%. As a group, equities research analysts forecast that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Insiders Place Their Bets

In other Celldex Therapeutics news, insider Richard M. Wright sold 49,298 shares of the business’s stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $24.00, for a total transaction of $1,183,152.00. Following the sale, the insider owned 20,833 shares in the company, valued at approximately $499,992. The trade was a 70.29% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 4.40% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Celldex Therapeutics in a research note on Wednesday, October 8th. Barclays lowered their target price on Celldex Therapeutics from $25.00 to $21.00 and set an “underweight” rating for the company in a research report on Tuesday, November 11th. Citigroup lowered their price objective on Celldex Therapeutics from $56.00 to $48.00 and set a “buy” rating for the company in a research note on Wednesday, August 20th. Mizuho began coverage on shares of Celldex Therapeutics in a report on Tuesday, October 21st. They set an “outperform” rating and a $48.00 price target on the stock. Finally, Wells Fargo & Company lowered their target price on shares of Celldex Therapeutics from $44.00 to $38.00 and set an “overweight” rating for the company in a research note on Wednesday, August 20th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Celldex Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.80.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.